Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin? - Wikidata - wikimedia - TriplyDB

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

http://www.wikidata.org/entity/Q40215585

about

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study.

P2860

Q41164717-34482323-617A-4213-A443-B2DF2DC3DCC4

P2860

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

http://www.wikidata.org/entity/Q40215585

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

@en

type

label

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

@en

prefLabel

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

@en

P1433

Q40215585-A55A6879-B3B6-47F5-9381-E37B11D4387E

P1476

Q40215585-20C7759C-4F09-457E-B5FF-D80422936579

P2093

Q40215585-12409045-3105-49CD-8408-3F2570A79973

Q40215585-127D50EB-993C-4089-B34A-436D24B2DA3D

Q40215585-1366E543-E316-4CB8-B0BF-E93B2A273A74

Q40215585-1BE24718-6784-4E00-971A-552DD15D45C1

Q40215585-4738F145-7271-4619-89F9-161EAFEAA8E3

Q40215585-4B720389-9CDF-4504-A429-844D8450C76B

Q40215585-8F06464B-7896-4C67-98EB-D0241FC2B36D

Q40215585-B096F9B9-57EF-4830-85D1-39BBADDF7DFD

P2860

Q40215585-2EF4D36E-698E-44AD-B83D-A653ED9B7B3F

Q40215585-32100EA5-C4CA-4FE5-92D8-9CD50784FFD0

Q40215585-3F160BE2-A96E-4B28-93CC-F3FEC175A576

Q40215585-40E97892-1617-4C0B-A684-702AEF7D0E90

Q40215585-71EA41B5-0AC9-4DC2-B178-98205AAB20F6

Q40215585-81E84320-E45E-4E64-ADF2-9C3E7F480244

Q40215585-9743437A-34C2-44C3-BDBC-83564C5B0DC2

Q40215585-D49E0E55-6D05-4BCA-B901-A8A4B6570828

Q40215585-EE3D8A21-F8E1-4BE0-B06F-9270D3DA7EBE

Q40215585-F4FB5E48-DCD5-4645-A2A3-866E2AC90DA3

P304

Q40215585-FB5C8A0F-F6F2-4F61-B897-CADF03504E1A

P31

Q40215585-59DB3A5F-84EC-4248-8F85-8C76989691A2

P356

Q40215585-76ADF9A8-89BA-4621-822F-9B6AC19F2ED2

P433

Q40215585-631D49E3-337A-414E-8E8F-50A3FFDFE5A7

P478

Q40215585-235FB8AA-10AE-4531-BA2C-A32E47D1D6C6

P577

Q40215585-831BAF0C-4F8E-4F71-A7A8-1AA10D88B483

P698

Q40215585-BAF6EEF1-D6F3-44FA-B16E-33B89BE7BE91

P356

P1433

Lower urinary tract symptoms

P1476

Does Baseline Prostate Volume Affect the Short-Term Outcome of Tamsulosin?

@en

P2093

Eiji Sato

http://www.w3.org/2001/XMLSchema#string

Hiroki Horita

http://www.w3.org/2001/XMLSchema#string

Ken-Ichi Sunaoshi

http://www.w3.org/2001/XMLSchema#string

Koh Takeyama

http://www.w3.org/2001/XMLSchema#string

Naoya Masumori

http://www.w3.org/2001/XMLSchema#string

Noriomi Miyao

http://www.w3.org/2001/XMLSchema#string

Taiji Tsukamoto

http://www.w3.org/2001/XMLSchema#string

Yoshinori Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the Comb

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

Outline of JUA clinical guidelines for benign prostatic hyperplasia.

Influence of prostate size on terazosin efficacy.

Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?

Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.

Alpha-blocker test: alternative to pressure-flow study of bladder outlet obstruction and detrusor contractility in patients without an enlarged prostate.

Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia.

Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.

P304

113-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/LUTS.12032

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26663551

http://www.w3.org/2001/XMLSchema#string